BioWa Licenses POTELLIGENT(R) Technology to Major Pharmaceutical Company for bi13281900 BioWa, Inc. announced today that has licensed POTELLIGENT® Technology to Novartis for the development of antibody therapeutics enhanced antibody-dependent cytotoxicity

BioWa Licenses POTELLIGENT(R) Technology to Major Pharmaceutical Company for bi13281900 ATTENTION EDITOR, HIGH TECHNOLOGY DESK..

BioWa Licenses POTELLIGENT(R) Technology to Major Pharmaceutical Company for bi13281900 BioWa, Inc. announced today that has licensed POTELLIGENT® Technology to Novartis for the development of antibody therapeutics enhanced antibody-dependent cytotoxicity

BioWa Licenses POTELLIGENT(R) Technology to Major Pharmaceutical Company for bi13281900 ATTENTION EDITOR, HIGH TECHNOLOGY DESK..

Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable R bi13281900 Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented an update of an ongoing phase 1 clinical trial for BiTE(R) antibody blinatumomab (MT103/MEDI-538) at the 10th International Conference on Malignant Lymphomas (ICML) Lugano, Switzerland

BioWa licenses Potelligent technology to Novartis (Pharmaceutical Business Re bi13281900 BioWa has licensed Potelligent technology to Novartis for the development of antibody therapeutics enhanced antibody-dependent cytotoxicity

AsiaNet Daily Summary - Press Releases for Thursday, June 12, 2008 (Thaipr.net) bi13281900 YAMAHA DEVELOPS TOKYO - Yamaha Corporation has announced the development of YMU809 audio codec IC that brings high-quality audio processing and hands-free functions to personal naviga..

AsiaNet Daily Summary - Press Releases for Thursday, June 12, 2008 (Bernama v bi13281900 ATTENTION EDITORS SYDNEY, June 12 /AsiaNet/ -- YAMAHA DEVELOPS TOKYO - Yamaha Corporation has announced the development of YMU809 audio codec IC that brings high-quality audio processing and hands-free functions to personal navigation devices, mobile phones, and other devices. www.global.yamaha.com BAYAN NETWORKS MOUNTAIN VIEW - Customers of Bayan ..

ImClone Appoints Dr. Bernhard Ehmer Senior Vice President and Managing Direct bi13281900 ImClone Systems Incorporated (NASDAQ: IMCL), a global leader the development and commercialization of novel antibodies to treat cancer, today announced that has appointed Bernhard Ehmer, M.D. as Senior Vice President and Managing Director, International Operations, effective May 30, 2008

European Medicines Agency recommends Erbitux for use (Pravda) bi13281900 Erbitux , a chimeric monoclonal antibody, received Friday approval recommendations from the European Medicines Agency (EMEA). An epidermal growth factor receptor (EGFR) inhibitor was recommended for a first-line treatment of metastatic colorectal cancer patients a certain genetic profile

New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Effi bi13281900 ImClone Systems Incorporated (NASDAQ: IMCL), a global leader the development and commercialization of novel antibodies to treat cancer, today announced data from new analyses of a pivotal Phase 3 trial that demonstrate increased ..

New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Effi bi13281900 NEW YORK----ImClone Systems Incorporated , a global leader the development and commercialization of novel antibodies to treat cancer, today announced data from new analyses of a pivotal Phase 3 trial that demonstrate increased efficacy of ERBITUX® first-line metastatic colorectal cancer patients the "wild-type" K-Ras biomarker

RTOG Study: Adding Cetuximab to Chemotherapy and Radiotherapy Leads to Improv bi13281900 Radiation Therapy Oncology Group (RTOG) investigators and ImClone Systems Incorporated (Nasdaq: IMCL) today announced that adding the biologic agent cetuximab (ERBITUX®) to chemotherapy and radiotherapy for patients inoperable ..

Xbox Backup Software - Home